Increased Serum VEGF-B Level Is Associated With Renal Function Impairment in Patients With Type 2 Diabetes
Yaping Wei, Shiyu Han, Ruonan Zhou, Pingyuan Xu, Lingyan Zhou, Ziwei Zhu, Yue Kan, Xiaoying Yang, Yingying Xiang, Yue Cao, Jin Yu, Jing Yan, Xizhong Yu, Xin Wang, Wenbin Shang
Abstract
Aims/Introduction Renal function impairment related to type 2 diabetes (T2DM) presents serious threat to public health. Previous studies suggest that vascular endothelial growth factor-B (VEGF-B) might contribute to renal injury. Therefore, this study investigated the association of serum VEGF-B level with the risk of renal function impairment in T2DM patients. Materials and Methods Serum VEGF-B levels were measured in 213 patients with type 2 diabetes and 31 healthy participants. Participants with type 2 diabetes were further divided into a group of 112 participants with eGFR<90 mL/min/1.73m 2 and 101 participants with eGFR≥ 90 mL/min/1.73m 2 . Clinical data were collected, and a binary logistic regression model was employed to test the association between potential predictors and eGFR. Results Serum VEGF-B levels evaluated in type 2 diabetes patients compared with healthy controls. In patients with type 2 diabetes, serum VEGF-B level was positively correlated with triglyceride, serum creatinine and cystatin C while negatively correlated with HDL-C and eGFR. Binary logistic regression showed that serum VEGF-B level was an independent risk factor of eGFR<90 mL/min/1.73m 2 . Conclusions Serum VEGF-B level is associated with renal function impairment in patients with type 2 diabetes and may be a potential drug target for diabetic kidney disease.